Vaccines, Immunology and Clinical Trials

About Conference

It is our immense pleasure to welcome all the Researchers, Efficient Scientists, Delegates, and Professors across the world to participate in its upcoming 6th International Conference on Vaccines, Immunology and Clinical Trials during March 23-24, 2023 in Amsterdam, Netherlands and highlights the theme "Navigation to Recovery - Exploring New Therapeutic Dimensions in Vaccination & Immunology" which includes various research findings of Vaccines and Immunology.

Our Organization works on 1000+ Global Events inclusive of 350+ Conferences, 550+ Upcoming and Previous Symposiums and workshops across Europe, the USA and Asia with the support of scientists and societies and Publishes 700 + Open Accessing Journals containing about one lakh famous identities, eminent scientists and researchers.

Vaccines R&D 2023 meeting highlights profoundly illuminating and intelligent sessions to empower the trading of thoughts over a wide scope of controls in the field of Vaccines, Immunology, and Clinical Trials. The gathering incorporates keynote talks from educated researchers, Plenary sessions, Poster Presentations, Young Researcher sessions, Symposiums, Workshop, and Exhibitions. There will be open doors for those picked to introduce themselves at the gathering to distribute an original copy dependent on their introduction in the Journal of Clinical Trials or its sister publication, Journal of Clinical Immunology and Allergy and Journal of Immunology, and Immunotherapy.

Venue & Hotel Details

Radisson Blu Hotel Amsterdam Airport, Schiphol Address: Boeing Avenue 2 Amsterdam Airport Schiphol, 1119 PB Schiphol-Rijk, Netherlands

Sessions & Tracks

Track 1: Vaccines

Vaccination is more important in our life for keeping us healthy. It helps us to fight against many chronic diseases like smallpox, measles, Influenza, etc. The eradication of smallpox is highly achieved by vaccine discovery. A vaccine contains disease-causing microorganisms like bacteria and viruses. The agents present in the vaccine when vaccinated stimulate the immune system and it gets recognized and the body’s immune system eliminates the infection. But vaccines remain elusive for the treatment of many important diseases like Herpes, Malaria, Ebola, HIV, etc. This Conference brings out the knowledge about the recent research and future aspects of Vaccines.

Track 2: Immunology

The main function of the immune system is to fight against the antigens that enter the body. It also can recognize the self and non-self-antigens. Immunology also deals with immunological disorders like graft rejection, hypersensitivities; autoimmune diseases. It contains the branches like innate and adaptive immunities. The adaptive immune system mediates the cell-mediated and humoral immune responses.  The research and development in immunology also now targeted the animals and new therapeutics were invented against the diseases that were infecting the animals. The immunoglobulin molecules play an important role in the immune system by neutralizing the antigens.  

Track 3: Vaccine Types

The Vaccines type includes Recombinant Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, and Conjugate Vaccines. The Attenuated Vaccines were first developed against the viruses. The first Vaccine developed using live attenuated virus was the Rabies Vaccine. Inactivated viruses contain killed microorganisms. U.S Childhood Immunization Schedule recently recommended the Live, Attenuated Vaccines for MMR vaccine. The recombinant vaccine is developed by using the gene segment from the protein of a disease-causing organism.

Track 4: Stem Cell Immunology

The capacity of the pluripotent stem cells is of great advantage to repairing tissues, and cell replacement therapeutics for treating chronic or degenerative diseases. There are chances of developing immunogenicity in response to stem cell therapy which may cause severe adverse and fatal effects to an individual. Hence various measures and strategies are being developed for the effective control of stem cell immunogenicity.

Track 5: Pediatric Immunology

About 40% of children in the world having an allergic diagnosis are due to Infectious Diseases. Paediatric Immunology mainly covers the areas of Infectious Diseases and allergies. A child’s Immune system responds with problems when the child has allergies. Commonly the paediatrician meets the child with asthma, sinus inflammations, pneumonia, eczema and these unusual conditions called anaphylaxis. The allergy is an extreme health problem in children. The recent advancements in paediatric immunology greatly help the General Practitioners for recognising allergy-related problems.

Track 6: Paediatric Vaccines

In recent years, the widespread of infectious diseases in children has decreased by the paediatric vaccines. The common Paediatric vaccines are Smallpox Vaccine, Hepatitis B vaccine, Diphtheria Tetanus and Pertussis Vaccines, Inactivated Polio Vaccine, Measles Mumps and Rubella Vaccine. Infectious diseases were once the leading cause of death in children. Now, fewer number deaths of children take place due to effective immunization.

Track 7: Chicken Pox Vaccines

The varicella vaccine is given for immunization against chicken pox which is a very common, contagious and fatal disease among children as it may cause serious complications. A booster shot is administered for children at 4 to 6 years of age. It is 85% effective in preventing mild illness and has less chance of an allergic reaction with any vaccine. Getting vaccinated is the best way to prevent chickenpox

Track 8: Zika Virus Vaccines

The live-attenuated vaccine is developed for the disease caused by Zika Virus. The monovalent version of the vaccine is designed against Zika virus infection. Zika Virus belongs to the Genus Flavivirus, which is transmitted by the Aedes mosquitos.  The understanding of flavivirus particle structure, the definition of E dimers as the key antigenic target, and a deep understanding of neutralization mechanisms help to develop the vaccine.

Track 9: Therapeutic Cancer Vaccines

The therapeutic cancer vaccines found to have more clinical benefits in cancer treatments. Immunosuppressive cancer microenvironments are the root cause of the lack of cancer eradication. The specific nature of the therapeutic cancer vaccines combines with immunomodulation which offers an attractive avenue for the development of future cancer therapies.

Track 10: Onco-Immunology

A well-known application in Cancer Immunology is Cancer Immunotherapy. Knowledge of the basic mechanisms of cancer immunology has been increasing rapidly. The current research and new findings have created these advancements to breakthroughs for many tumours. Oncologist aims to know the relationship between cancers and the normal immune system. The molecular identification of cancer antigens, Cytokine gene transfer into cancer cells, and adoptive transfer of immune effector cells are some of the recent progress in cancer immunology.

Track 11: Recombinant Vaccines

The recombinant vaccine is developed through recombinant DNA technology. These Vaccines are produced by the insertion of genetic material which encodes the antigen that stimulates an immune response. Plasmid DNA is used as a vaccine which is propagated in bacteria like E.Coli and they get isolated and purified into the vaccine.

Track 12: Flu Vaccines

Influenza is a chronic disease that leads to even death in serious conditions. About millions of people get flu, every year and tens of thousands die from flu-related diseases. Taking the annual seasonal flu vaccine is the only way to decrease the risk of getting an infection with seasonal flu which can spread to other people.

Track 13: Allergy & Asthma Vaccines

The most common allergies like hay fever or house-dust mite allergy are treated using allergy vaccines. Allergy vaccines are more ejective in treating the insect stings like bee and wasp stings, which can be fatal in severe cases. The allergy vaccination is used in graduated doses beginning with a very small dose and it increases gradually. 

Track 14: HIV Vaccines

Currently, there is no vaccine available for HIV to prevent or treat. The long-term goal is to develop safe, effective and affordable vaccines for preventing infection in uninfected people. The difficulties faced by researchers in developing the HIV vaccines are that HIV structure changes frequently and HIV isolates are themselves highly variable.

Track 15: HPV Vaccines

The HPV vaccines like Gardasil, Gardasil 9, and Cervarix were approved by the FDA. These vaccines prevent infections with HPV types 16 and 18. The HPV types 6 and 11 are prevented by the vaccine Gardasil. The phenomenon is called cross-protection in which the vaccines are found to provide some protection against a few additional HPV types.

Track 16: Infectious and Non-infectious diseases Vaccines

More usage of Vaccines has decreased the infectious and non-infectious diseases among infants and adults. Many chronic infectious and non-infectious diseases are highly treated using recent technologies and advanced research in monoclonal antibodies. The present challenge in the vaccination world is to develop vaccines for diseases which will consistently maintain the antibody responses in the human body. Some Vaccines give immunity over life whereas some require booster shots. However, currently developing vaccines were more likely to develop effective immunity.

Track 17: Plant Vaccines & Veterinary Vaccines

Apart from developing vaccines for animals and microorganisms, the development of vaccines for plants also plays an important role in acting against many chronic diseases. The implementation of several plant vaccines takes more effort and time. Mucosal immunity and systemic immunity are highly conferred by plant-made antigens through oral vaccination.

Veterinary Vaccines were proved to be beneficial for animal health. Animal diseases like Canine parvovirus, Canine distemper, Feline leukaemia, and Equine tetanus have been reduced more and also eliminated by the vaccines. Unfortunately, currently, it is unable to make the individual vaccine program for animals to assure protection from disease and completely prevent adverse reactions.

Track 18: Transplant Immunology

Transplant immunology is more about the rejections that take place during the transplantations. It is the study of the immunologic reaction of a recipient due to transplanted organs or tissues from a histo-incompatible recipient. The immune response depends on the presence of antigens in the grafted tissue. If these antigens are absent in the recipient it is recognized as a foreign substance.

The transplant rejection can be reduced by taking the immunosuppressive drugs before and after transplantation and checking the match between the donor and recipients. The transplant rejection is the response of the adaptive immune system by both cellular immunity and humoral immunity.

Track 19: Clinical Immunology & Immunopathology

Clinical immunology is the study of diseases caused by disorders of the immune system (failure, aberrant action, and malignant growth of the cellular elements of the system). It likewise includes infections of different frameworks, where safe responses influence the pathology and clinical highlights.

Other immune system disorders include various hypersensitivities (such as asthma and other allergies) that respond inappropriately to otherwise harmless compounds.

The most well-known disease that affects the immune system itself is AIDS, an immunodeficiency characterized by the suppression of CD4+ ("helper") T cells, dendritic cells and macrophages by the Human Immunodeficiency Virus (HIV).

Clinical immunologists are examining approaches to keep the resistant framework's endeavors to annihilate allografts (transplant rejections).

Track 20: Antibodies Research

The antibody is also known as immunoglobulin which is a large molecule synthesized by the plasma cells and they are utilized by the immune system to neutralize the antigens. The binding mechanism of the antibody can tag the microbe or the infected cell for attack by the other parts of the immune system. The humoral immune system mainly functions by producing antibodies.

Track 21: Travel & Edible Vaccinations

Vaccination before travel is imperative to ensure the global public health and to help individuals stay healthy during and after their travels. As such, Passport Health is committed to ensuring maximum immunization coverage in all populations from children, to members of the workforce, to the elderly, to international travellers via our nationwide clinic network.

Travel antibodies are prescribed to protect travellers from serious diseases. Contingent upon where you travel, you may come into contact with infections that are uncommon, similar to yellow fever. A few immunizations may likewise be required for you to travel to certain places. They are proposed to ensure explorers and to avert infection spread inside and between nations.

Eatable antibodies hold incredible guarantee as a financially savvy, simple to-direct, simple to-store, safeguard and sociocultural promptly adequate immunization conveyance framework, particularly for the poor creating nations. It includes the presentation of chosen wanted qualities into plants and after that actuating these changed plants to fabricate the encoded proteins.

Getting vaccinated will help keep you safe and healthy while you're voyaging. It will likewise help ensure that you don't convey any rare diseases home to your family, companions, and network

Track 22: Immune System Disorders

The immune system is the complex networking of cells, tissues and organs that helps us to fight against germs. The most common immune disorders are allergy and asthma. The characterization of the immune system could be done with the help of the components of the immune system getting affected, overactive or underactive of the immune system.

Track 23: Vaccines Efficacy and Safety

In the last two centuries, Vaccines plays an important role in providing a safe and effective means of preventing several diseases. But the safety of some vaccines has been doubted in recent years. But compared to the infection of the diseases the vaccines are a million times safer than them. New systems were developed for the production of vaccines.

Track 24: Immunization Challenges

Vaccination efforts are challenging for 35 lower-middle countries. Nearly 24 million unimmunized or incompletely immunized children are living in the poorest countries. Loss of public confidence because of real or spurious links to adverse events halts immunization activities in both developed and industrialized countries.

Track 25: Vaccines and Immunology Advancements

The recent advancements in vaccines protect people from a wide variety of diseases. The main ability of the vaccines is to induce the humoral antibody responses and cell-mediated responses against a wide range of pathogens. Additionally, the invention can be used to produce vaccines, immunogens and valuable therapeutic and diagnostic reagents.  

Track 26: Vaccine-Induced Immunity

Vaccine-induced immunity is the artificial induction of immunity to specific diseases by making the people immune to disease by means other than waiting for them to catch the infection. Vaccine-induced immunity has been assessed for various infections which also include HIV-1. The incidence of HIV infection is higher in vaccine treated than in placebo-treated men with pre-existing adenovirus serotype 5 immunity.

Participation / presentation options

Oral presentation: Oral Presentations may include the topics from researches, theoretical, professional or private practices in a concise manner. Individuals with personal experience are also welcome to present personal experiences or narratives which help others in everyday life. Speakers with a 30-minute slot should plan to speak for 20-25 minutes, and Keynote speakers should plan to speak for 40-45 minutes, with the remaining time to be used for questions and discussion by the Session Chair.

Workshop: For workshop presenters also, the topic of the talk will be the same as an Oral presentation with more specialized techniques and detailed demonstration. The generalised time duration for a workshop presentation is about 45-50 minutes. Interested participants can join their respective teams and present the workshop with their research coordinators with special group waivers on registration.

Poster presentation: Student Poster Competition will be organized at the Vaccines R&D 2023 conference to encourage students and recent graduates to present their original research. Presenters will be given about 5-7 minutes to present the poster including questions and answers. Judges may ask questions during the evaluation of the presentation. This is an opportunity for young scientists to learn about the recent findings of their peers to increase their capacity as multidisciplinary researchers. Poster displays will be in hard copy format of 1x1 M long.

For more details regarding Poster Presentation and Judging Criteria view Poster Presentation Guidelines.

Webinar: The webinar presentation is designed for those interested attendees who cannot join in person due to schedule conflicts or other obligations. In this option, the presenter may record the presentation and their presentation will be presented in the Webinar presentation session.

E-Poster: e-Poster is also similar to the webinar presentation. In this session, their presentation will be published in the form of a poster on the conference website and the presenter's abstract will be published in the conference souvenir and journal with DOI.

Exhibition: Vaccines R&D 2023 has the opportunity to exhibit the products and services from commercial and non-commercial organizations like Drug manufacturers, Clinical Trial Sites, Management Consultants, Chemists, Pharmacists, Business delegates and Equipment Manufacturers.

To know more about exhibitor booth details and benefits visit WHY TO EXHIBIT WITH US?

Send your queries to vaccineresearch@europeanmeets.com

Advertisement: The conference program is a valuable resource that all attendees refer to again and again as they navigate the conference. Advertising in the conference program is an excellent way to market and can help you secure long-term business.

Send your proposal to vaccineresearch@europeanmeets.com to know the available advertisement options and prices

Sponsor Vaccines R&D 2023

• Premium Sponsorship package
• Additional Sponsorship package

Mail the program manager at vaccineresearch@europeanmeets.com or WhatsApp on (+44 1371 290000 to know more about the sponsorship packages.

Abstract Submission Criteria & Eligibility

PRESENTATION REQUIREMENTS:

• Presenting authors are responsible for registration, travel, and hotel costs. Note: Those with accepted abstracts will receive an acceptance mail allowing them to register for the conference.
• Abstracts will be compiled and conference books are made available to participants at the conference.
• Any presenter who is unable to attend should arrange for another qualified individual to present the paper/poster in question. If such a change is necessary, please notify our conference team

SUBMISSION OPTIONS:

• Oral paper presentations will have 30-minute time slots and be clustered by theme into sessions. The keynote session will have a 45-minute time slot, the workshop/ special session will have a 60-minute time slot and the symposium will have a 60-minute time slot followed by a 5-minute Q&A session.
• Graduate & Masters's students are eligible to submit their abstracts under the poster and e-poster presentation category.
• PhD students are eligible to submit their abstract under the special YRF (young researcher’s forum), poster and e-poster presentation category. NOTE: YRF category includes short oral presentations, especially for Ph. D. students
• Extended abstract: Submissions should utilize the Abstract Template. Papers submitted in this category may represent original empirical research, theoretical development, reviews, or critiques.

VISA Application

Vaccines R&D 2023 organizing committee hereby reiterates that we are NOT authorized to assist with any Visa application works. You may be required to submit a Letter of Invitation, Letter of Abstract Acceptance and Registration Payment Receipt to the embassy. 

Letter of Invitation: A Letter of Invitation is proof that your paper submission and registration application are accepted by the conference committee board. It will be stated in English and may help with your visa application.  

Token Amount: Token amount of USD 100 can be paid and a payment receipt can be proof of payment and may help with your VISA application.   

**SHOULD YOUR APPLICATION BE DENIED, VACCINE RESEARCH 2023 ORGANIZING COMMITTEE CAN NOT CHANGE THE DECISION OF THE MINISTRY OF FOREIGN AFFAIRS, NOR WILL WE ENGAGE IN DISCUSSION OR CORRESPONDENCE WITH THE MOFA OR THE EMBASSY ON BEHALF OF THE APPLICANT. THE REGISTRATION FEE WILL BE REFUNDED WHEN THE VISA APPLICATION OF THE INDIVIDUAL IS DENIED AND SHOULD SUBMIT VISA REJECTION PROOF**

Market Analysis

SUMMARY

International Congress on Vaccines & Immunology is recognized internationally and it mainly focuses on the exchange of ideas all over the world.

The conference will include seminars, Oral presentations, Poster presentations, Symposiums, and Workshops which will be a great platform for all the academic Researchers and Scientists to exchange their Innovations and Technology. 

The main aim of the conference is to focus on new Therapeutic technologies and recent advancements in Vaccines and Immunology.

Our Organization works on 1000+ Global Events inclusive of 350+ Conferences, 550+ Upcoming and Previous Symposiums and workshops across Europe, the USA and Asia from the support of scientists and societies and Publishes 700 + Open Accessing Journals containing about 1 lakh famous identities, eminent scientists and researchers.

IMPORTANCE & SCOPE:

Vaccination belongs to an important and effective way of infectious disease prevention. Vaccines and Immunizations are considered a few measures for public health and safety. It is said that diseases such as diphtheria, polio, smallpox etc., are becoming rare due to vaccinations and thus they help not only in providing individual protection but also community protection by preventing the spread of diseases within the population. It is believed that vaccines are the most cost-effective medication for people as they not only save lives but also greatly reduce spending on future healthcare. Vaccination is considered a cutting-edge marvel for public health thus improving the quality of life. Many examples stand out for vaccinations being a life saviour and eradicating serious effects of diseases. There will be many more potentially lifesaving vaccines in the years to come. Research is thriving, with more than 150 new vaccines currently being tested.

The initiatives being taken by the governmental organizations for vaccination awareness programs are bringing issues to light about vaccinations and the immunizations that need to be taken during childhood days, adolescence and the senior people.

MARKET ANALYSIS

The vaccines market was USD 49.27 Billion in 2017, at a CAGR of 7.5% and is expected to reach USD 114.2 Billion by 2028. The CAGR for the Global Vaccines Sales market from 2018-2028 is expected to be 10.9%.

The vaccine market has grown due to an increase in the prevalence of diseases, and an increase in government, non-government and industrial funding.

The prospective signifies a major growth in the vaccine market but due to high costs associated with the vaccine development, the market growth may be retarded.

The vaccines market provides all the inclusive details of the global market, particularly in North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The CAGR is expected to be the highest in the North American region followed by the Asia Pacific and Europe is accounted to be the third-largest market, over the forecast period.

PHARMAC announced the approval of an agreement to fund the Zoster vaccine (Zostavax) from 1st April 2018.

People who meet the funding criteria can receive their zoster vaccine at the same time as their annual influenza vaccine.

INFLUVAC® TETRA (Mylan) is the funded influenza vaccine for adults and children aged 3 years or older.

FLUARIX® TETRA (GSK) is the funded influenza vaccine for children aged less than 3 years, i.e. aged 6–35 months.

The vaccine market is highly competitive with several big and small players. The key players in the market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co., Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur SA (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Protein Sciences Corporation (U.S) and Panacea Biotech (India).

The National Immunization Program of Australia aims to increase national immunization rates by funding free vaccination programs and communicating information about immunization to the general public and health professionals.

As they make an effort to control the use of the medicinal service, governments have been attempting persistent endeavours to diminish the cost of patient inoculation through different immunization programs subsidized by the government and private health authorities. The Vaccines for Children Program, for example, gives antibodies to children who need medical coverage or who can't bear the cost of inoculation. Financing is given through the Centers for Medicare and Medicaid Services (CMS) to the Centers for Disease Control (CDC) and endorsed by the Office of Management and Budget.

Ascend in take-up of new antibodies has prompted an expansion in worldwide immunization scope. As indicated by WHO, inoculation counteracts around 3 million deaths worldwide consistently, and an extra 1.5 million deaths could be maintained at a strategic distance if the immunization scope progresses. As per a report discharged in 2015 by the Centers for Disease Control and Prevention (CDC), inoculation was assessed to anticipate around 21 million hospitalizations, 322 million ailments, and 732,000 deaths in kids conceived in the vicinity of 1994 and 2013, which could spare around USD 1.4 trillion in societal expenses. By 2016, DTP antibody scope had come to roughly 90% in more than 130 nations around the world.

As these areas grow both in their need and the ability and willingness of the healthcare systems to pay, further growth in vaccine sales is expected. These emerging markets are just one factor in the overall vaccine sales growth expected, but it is a significant one.

Target Audience:

Academia - 40%

Industry   –   35%

Association and societies - 15%

Other Health care Professionals -10%

• Immunologists
• Vaccinologists
• Vaccine Developers and Investigators
• Vaccine & Immunology Emeritus Professors
• Immunology Researchers
• Vaccine & Immunology Scientists
• Vaccine & Immunology Professors
• Chairmen, CEOs, Presidents, Vive-presidents, Directors, Deans, Research Scholars
• Medical faculty & staff
• Clinical Microbiologists
• Associations and Societies related to Vaccine R&D
• Immunology Societies & Associations
• Vaccines Training Institutes
• Medical Devices Companies
• Vaccine Manufacturing Companies
• Clinical Data Management Companies
• Medical Equipment Companies

Major associations around the Globe for Vaccine and Immunology Research

• European Federation for Immuno-genetics
• European Society for Immunodeficiency
• American Association of Immunologists
• American Association of Veterinary Immunologists
• Australasian Society for Immunology
• British Society for Allergy and Clinical Immunology
• British Society for Immunology
• Society for Mucosal Immunology
• International Society of Travel Medicine
• The International Society of Neuro-immunology
• The International Union of Immunological Societies
• The Society for Travel Immunology
• The Society for Leukocyte Biology
• Transplantation Society
• British Society for Immunology
• Cell Death Society
• European Federation of Immunological Societies
• European Society of Gene Therapy
• Federation of African Immunological Societies
• Federation of American Societies for Experimental Biology
• Federation of Clinical Immunology Societies
• Immune Deficiency Foundation
• Infectious Diseases Society of America
• Companies Associated with Vaccines Research and Production
• CareDx
• Atara
• Activities        
• AFFiRiS          
• Hookipa Biotech Vienna,
• s-TARget Therapeutics
• Themis Bioscience       
• Valneva
• Biotherapeutics
• Benitec Limited
• InterMune
• Biotron Limited
• Diem
• Antisense Therapeutics Limited      
• GlaxoSmithKline USA Pty Ltd
• Bionomics
• USA Pharmaceutical Industries (API)  
• BioPharmica Limited

Hospitals Associated with Vaccine Research and development

• Johns Hopkins Hospital Baltimore U.S
• Chris Hani Baragwanath Hospital Johannesburg South Africa
• Stanford Hospitals and Clinics U.S
• Great Ormond Street Hospital London the UK
• University of Texas MD Anderson Cancer Centre Houston the U.S
• Harvard Medical School Boston U.S
• Karolinska Hospital, Stockholm, Sweden
• The Priory UK
• Bumrungrad International Hospital Bangkok Thailand
• Cedars-Sinai Medical Center Los Angeles U.S